中国药物警戒 ›› 2025, Vol. 22 ›› Issue (9): 1051-1053.
DOI: 10.19803/j.1672-8629.20240860

• 安全与合理用药 • 上一篇    下一篇

注射用尖吻蝮蛇血凝酶致严重过敏性休克1例分析

钱凤丹1, 张立超1, 贡翊斐2,*   

  1. 1上海中医药大学附属市中医医院药学部,上海 200071;
    2上海中医药大学附属市中医医院外三科甲乳血管外科,上海 200071
  • 收稿日期:2024-11-06 发布日期:2025-09-22
  • 通讯作者: *贡翊斐,女,主治医师,微创手术结合中医治疗诊治甲乳疾病。E-mail: 578924160@qq.com
  • 作者简介:钱凤丹,女,主管药师,临床药学与药品不良反应监测。
  • 基金资助:
    上海申康医院发展中心市级医院诊疗技术推广及优化管理项目（SHDC22024202）; 上海市卫生健康委员会中医药科研项目—青年引导类项目（2024QN001）

One Case of Severe Anaphylactic Shock Caused by Hemocoagulase Agkistrodon for Injection

QIAN Fengdan1, ZHANG Lichao1, GONG Yifei2,*   

  1. 1Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China;
    2Department III of Surgery, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
  • Received:2024-11-06 Published:2025-09-22

PDF (PC)

42

摘要： 目的 探讨围术期出血患者使用注射用尖吻蝮蛇血凝酶致严重过敏性休克的病例特征,为临床安全用药提供参考。方法 分析1例乳腺癌患者术后使用注射用尖吻蝮蛇血凝酶止血时发生严重过敏性休克病例,并对国内外相关文献进行归纳总结。结果 患者使用尖吻蝮蛇血凝酶后立即发生严重过敏性休克,时间上存明显关联性,停药及对症处理后转归良好。文献显示使用尖吻蝮蛇血凝酶后发生过敏性休克的时间均在30 min内,有无过敏史的患者均有发生过敏性休克的风险。结论 注射用尖吻蝮蛇血凝酶致过敏性休克风险存在不可预知性,临床应引起重视,在高危人群中用药前应充分评估安全性,并做好发生不良反应的应对抢救措施。

关键词: 尖吻蝮蛇血凝酶, 注射用, 乳腺癌, 术后, 围术期出血, 过敏性休克, 药品不良反应

Abstract: Objective To investigate the characteristics of severe anaphylactic shock caused by hemocoagulase agkistrodon for injection in a patient with perioperative bleeding so as to provide a reference for safe clinical medication. Methods One case of severe anaphylactic shock that occurred after the use of hemocoagulase agkisttodon for injection for hemostasis in a breast cancer patient postoperatively was analyzed. Related literature was reviewed. Results The patient experienced severe anaphylactic shock immediately after using the hemocoagulase agkisttodon for injection. There was a significant temporal correlation. After quick symptomatic treatment, the patients recovered. Literature suggested that anaphylactic shock usually occurred within 30 minutes of using hemocoagulase agkistrodon. Patients with or without a history of allergies were at risk of anaphylactic shock. Conclusion The risk of anaphylactic shock caused by hemagglutinin is unpredictable, which deserves attention. Assessment of safety and precautions against adverse reactions should precede the use of this drug in high-risk populations.

Key words: Haemocoagulase Agkistrodon, Injection, Breast Cancer, Postoperative, Perioperative Bleeding, Anaphylactic Shock, Adverse Drug Reactions

中图分类号: